Clinical Features of COVID-19 in Patients with Congenital Central Hypoventilation Syndrome

Pediatr Allergy Immunol Pulmonol. 2023 Jun;36(2):52-56. doi: 10.1089/ped.2023.0004. Epub 2023 May 18.

Abstract

Background: The clinical course of COVID-19 in patients with congenital central hypoventilation syndrome (CCHS) is unknown. Methods: We conducted a cross-sectional questionnaire study in 43 patients with CCHS who had COVID-19. Results: The median age of patients was 11 [interquartile range (IQR) 6-22] years and 53.5% required assisted ventilation (AV) through tracheostomy. Disease severity ranged from asymptomatic infection (12%) to severe illness with hypoxemia (33%) and hypercapnia requiring emergency care/hospitalization (21%), increased AV duration (42%), increased ventilator settings (12%), and supplemental oxygen demand (28%). The median duration to return to baseline AV (n = 20) was 7 (IQR 3-10) days. Patients with polyalanine repeat mutations required increased AV duration compared with those with nonpolyalanine repeat mutations (P = 0.048). Patients with tracheostomy required increased oxygen during illness (P = 0.02). Patients aged ≥18 years took longer to return to baseline AV (P = 0.04). Conclusions: Our study suggests that all patients with CCHS should be vigilantly monitored during COVID-19 illness.

Keywords: CCHS; COVID-19; PHOX2B; home mechanical ventilation; tracheostomy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • COVID-19* / complications
  • Child
  • Cross-Sectional Studies
  • Homeodomain Proteins* / genetics
  • Humans
  • Oxygen
  • Transcription Factors / genetics
  • Young Adult

Substances

  • Homeodomain Proteins
  • Transcription Factors
  • Oxygen

Supplementary concepts

  • Congenital central hypoventilation syndrome